Navigation Links
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Date:11/15/2007

BRUSSELS, Belgium and BRISBANE, Calif., Nov. 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced it has initiated a Phase 2 study of its lead PARP inhibitor, BSI-201, in patients with triple-negative breast cancer that do not express the estrogen, progesterone or HER2 receptors.

The company designed the Phase 2 trial in this indication-which represents a major unmet medical need-based on molecular biomarker data presented today showing that breast tumors that are estrogen-negative and progesterone- negative were more likely to overexpress PARP, as were HER2-negative tumors. The data were presented at European Organization for Research and Treatment of Cancer-National Cancer Institute-American Society for Clinical Oncology Annual Meeting on "Molecular Markers in Cancer" in Brussels.

"Our research shows clearly that not only is PARP overexpressed in breast tumors generally, it is even more likely to be overexpressed in triple- negative tumors. That suggests that PARP inhibition may be a particularly effective way to target those hard-to-treat cancers," said BiPar Executive Vice President Barry Sherman, M.D. "Our Phase 2 trial of BSI-201 will build on those insights and, if successful, will serve as powerful proof of our strategy to use molecular biomarker data to focus our clinical studies of BiPar's PARP inhibitors on tumors that markedly upregulate PARP."

Patients with triple-negative breast cancer, who make up 10 to 15 percent of all patients, have few effective therapeutic options. Neither targeted therapies such as Herceptin and Tykerb nor anti-estrogens such as tamoxifen provide a benefit, and triple-negative tumors are associated with a high rate of relapse. Such cancers are particularly prevalent in premenopausal African- American women.

"We are very excited about being able to offer patients with triple- negative metastatic breast cancer treatment
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Enrollment Begins on Human PK Study for Medidur(TM) FA
7. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
11. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "China PTCA Balloon Market Investment Report, 2014-2016" ... as a indispensable medical device in percutaneous coronary intervention ... stent, but also as a device for pre-/post-stent dilatations. ... related to that of PCI. As national ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... , Sept. 18, 2014   Fruit Street ... secured an initial seed round of funding. ... was led by a series of individual investors, the ... whom participated in the initial round are; Houston ... Medical Center Urologist Stacy Childs, Rapha Family Medicine Practice ...
Breaking Medicine Technology:China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3
... 21 /PRNewswire-FirstCall / -- SPX Corporation (NYSE: ... the Anhydro business, a Soeborg, Denmark -based global supplier of ...  The terms of the transaction were not disclosed. , ... Anhydro supplies a wide range ...
... Young Innovations, Inc. (Nasdaq: YDNT ) today announced that its ... per share, payable September 15, 2010 to all shareholders ... Directors also authorized the repurchase of up to 500,000 shares of ... July 31, 2011 , replaces the current authorization which is scheduled ...
Cached Medicine Technology:SPX Completes Acquisition of Anhydro 2SPX Completes Acquisition of Anhydro 3Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program 2
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... scientists have developed a new method to study Ebola ... The Wildlife Conservation Society (WCS)-led research, published today in ... the use of fecal samples from wild great apes ... the virus. This represents a new tool for performing ... way Ebola virus is studied and improve our understanding ...
(Date:9/18/2014)... Dangerous new pathogens such as the Ebola virus invoke ... such as the bubonic plague are still providing researchers ... infections. , In a study published online Sept. 18, ... Duke Medicine and Duke-NUS Graduate Medical School Singapore detail ... hitchhike on immune cells in the lymph nodes and ...
(Date:9/18/2014)... Technology Association of Georgia in collaboration ... TAG Social Savvy Awards this week at a special ... Center in Downtown Atlanta. The event celebrates Georgia’s best ... was honored with the 2014 TAG Social Savvy People’s ... innovators in 6 other award categories: , ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:New insights on an ancient plague could improve treatments for infections 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3
... A group of Northeast Ohio breast,cancer survivors continue to ... the disease by participating in the sport of Dragon ... canoeing, involves a team of 22,paddlers racing in 40-foot-long ... the team offers women living with breast cancer an,opportunity ...
... Increasing temperatures, carbon dioxide levels add to discomfort of ... Add increased suffering for people with ragweed allergies to ... new study suggests. , Recent research indicates that ... longer ragweed seasons and more concentrated pollen counts, says ...
... certain genotype more affected, study finds , , MONDAY, Aug. ... containing codeine may be unwittingly risking the health of ... indicates that a relatively rare genetic predisposition causes some ... than normal -- possibly harming the infant,s central nervous ...
... at menopause as well as a woman,s breastfeeding practices ... breast cancer. That was the conclusion of a new ... CANCER, a peer-reviewed journal of the American ... distinct and separate hormonal risk factors associated with different ...
... Bikes Belong and Humana, launches Freewheelin ... bike-sharing initiative ... Inaugural Ride, DENVER, Aug. 24 Bike-sharing officially,rolled into Denver ... date: Freewheelin. Leading 100 cyclists,through the streets of Denver, Mayor Hickenlooper ...
... Benefit Group, LLC announces iCan Insurance, LLC ("iCan Insurance", "iCan") ... Inc. , ... Boca Raton, FL ... iCan Insurance, LLC ("iCan Insurance", "iCan") is now offering major ...
Cached Medicine News:Health News:Dragon Dream Team Continues to Send Message of Hope a Year Later 2Health News:Climate Change Linked to Longer Pollen Seasons 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 3Health News:Breastfeeding, other factors may affect risk of breast cancer type 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 3Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 4Health News:iCan Benefit Group, LLC Announces: Major Medical Division Now Offers Avalon Healthcare Products 2
Microwell-EIA for the detection of GAD Autoantibody....
The NPT7 blood gas analyzer measures pH/blood gases and oximetry on 90 L sample volume with a two-step sampling procedure. Clinical tests compare NPT7 accuracy to that of benchtop analyzers. 30 sampl...
... GEM Premier 3000 simplifies and ... addition to unique features such ... and comprehensive menu options, the ... Intelligent Quality Management (iQM), an ...
... IRMA TRUpoint sets the standard for ... chemistries right at your patient's side ... This powerful, self contained system can ... CCU to ICU, or wherever you ...
Medicine Products: